Alembic Pharmaceuticals Limited (APLLTD) reports a 26% YoY revenue surge in Q1 FY27, driven by strong growth in India Branded Business and US Formulation.
Alembic Pharmaceuticals Limited (APLLTD) secures USFDA final approval for Prucalopride Tablets, 1 mg and 2 mg, expanding its generic drug portfolio.
Alembic Pharmaceuticals Limited (APLLTD) announces USFDA final approval for Dapsone Gel, 5%, expanding its generic drug portfolio.
Alembic Pharmaceuticals Limited (APLLTD) announced USFDA final approval for Oseltamivir Phosphate Oral Suspension, 6 mg/mL, expanding its generic drug portfo.
Alembic Pharmaceuticals Limited (APLLTD) receives final approval from USFDA for Tretinoin Cream USP, 0.05%, with an estimated market size of US$ 76 million.
Alembic Pharmaceuticals Limited (APLLTD) secures USFDA tentative approval for Larotrectinib Capsules, marking a significant milestone.
Alembic Pharmaceuticals Limited (NSE: APLLTD) secures USFDA final approval for Haloperidol Tablets, expanding its generic drug portfolio.
Alembic Pharmaceuticals Limited (APLLTD) announces USFDA final approval for its Levothyroxine Sodium Tablets, expanding its generic drug portfolio.
Alembic Pharmaceuticals Limited (APLLTD) Q4 FY26 results show a 4% revenue growth, with significant gains in US Formulation and strong EBITDA margin.
Alembic Pharmaceuticals Limited (APLLTD) announced USFDA tentative approval for Darolutamide Tablets, 300 mg, with an estimated market size of US$ 3,155 million.